National Health Revocation Instrument 2012 (No. 1) (No. PB 55 of 2012)

Overview

The National Health Revocation Instrument 2012 (No. 1) was enacted to address the redundancy of the co-marketed brands determination for certain pharmaceutical items under the National Health Act 1953. This legislation was introduced to revoke the previous determination that treated specific brands of clopidogrel with aspirin as co-marketed brands, a status that no longer served a functional purpose after a third brand of the same pharmaceutical item was listed on the Pharmaceutical Benefits Schedule (PBS). The instrument, made pursuant to subsection 84AE(3A) of the Act, was issued by the Minister of Health and aimed to align the Act with the current market conditions, ensuring that the provisions of the Act remain relevant and effective. The policy objective behind this revocation is to maintain the integrity and efficacy of the health benefits scheme by adapting to changes in the pharmaceutical market. This revocation instrument ensures that the National Health Act 1953 continues to support the highest attainable standard of health by adjusting to the changes in the pharmaceutical market. The revocation of the co-marketed brands determination for DuoCover and CoPlavix brands of clopidogrel with aspirin reflects the dynamic nature of the health care landscape, where legislative measures must be flexible enough to adapt to new market entries and other changes. By revoking the outdated determination, the instrument ensures that the Act remains compatible with human rights, particularly the right to the highest attainable standard of physical and mental health, by facilitating access to essential medications through the PBS.

Scope and Application

The National Health Revocation Instrument 2012 (No. 1) pertains to the regulation of pharmaceutical items under the National Health Act 1953, specifically addressing the revocation of a prior determination concerning co-marketed brands of pharmaceutical products. This Act applies to pharmaceutical brands and entities involved in the marketing of such drugs within Australia. The instrument revokes the earlier determination identifying certain brands of clopidogrel with aspirin, DuoCover and CoPlavix, as co-marketed brands. This revocation is effective from the day following its registration on the Federal Register of Legislative Instruments, thereby ceasing their status as co-marketed brands and impacting their eligibility for certain pharmaceutical benefits listings. The revocation is authorised under subsection 84AE(3A) of the Act, which allows for the variation or revocation of co-marketed brand determinations when conditions such as the listing of another brand of the same pharmaceutical item are met. The instrument's jurisdiction is national, applying uniformly across Australia, and it does not include any specific exclusions beyond the criteria set out in the Act. Subordinate instruments may further define or extend the application of this revocation as needed.

Key Provisions

The main operative sections of the National Health Revocation Instrument 2012 (No. 1) (PB 55 of 2012) are found under subsections 84AE(3) and 84AE(3A) of the National Health Act 1953 (the Act). Subsection 84AE(3) (paragraphs omitted) allows the Minister to determine that two or more brands of a pharmaceutical item are co-marketed brands. This instrument revokes a previous determination made under this subsection (subsection 84AE(3)) for the brands DuoCover and CoPlavix, which were co-marketed brands of clopidogrel with aspirin in the form Tablet 75 mg (as hydrogen sulfate) - 100 mg with manner of administration Oral. Subsection 84AE(3A) allows the Minister to vary or revoke a co-marketed brands determination if certain conditions are met, such as the listing of another brand of the same pharmaceutical item on the Pharmaceutical Benefits Schedule (PBS). This instrument revokes the determination of DuoCover and CoPlavix as co-marketed brands, effective from the day after the instrument is registered on the Federal Register of Legislative Instruments. This Act imposes obligations and requirements on the Minister for Health, who is the individual responsible for making the determinations and variations or revocations of co-marketed brands. Under the Act, the Minister must ensure that the criteria for allocating drugs to formularies, particularly the criteria in section 85AB, are adhered to. The Act requires that co-marketed brands are treated as a single brand for the purposes of these criteria. Additionally, the Minister must monitor the listing of pharmaceutical items on the PBS and be aware of when conditions are met that allow for the revocation of a co-marketed brands determination. The Minister must also ensure that any revocations or variations are made in accordance with the legislative provisions and are registered on the Federal Register of Legislative Instruments. In terms of offences, penalties, or consequences for breach, the Act does not explicitly state penalties for non-compliance with the revocation of co-marketed brands. However, the Act and the broader legislative framework within which it operates, such as the Legislative Instruments Act 2003, may provide for penalties or consequences for improper administration or failure to comply with legislative requirements. For example, there may be administrative or legal consequences for the Minister or relevant authorities if they fail to properly revoke a co-marketed brands determination when conditions are met. The penalties could include fines or other administrative sanctions, but these are not specified in the Act itself. The revocation of the determination under this instrument does not carry a direct penalty for breach, as it is a machinery measure intended to update the regulatory framework rather than impose punitive measures.